Lead Product(s): PNT001
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PNT001
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Advanced Technology International
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding June 17, 2021
Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope that has been identified in multiple preclinical studies as a potent driver of neurodegenerative disease.